Which act provides financial incentives for pharmaceutical companies to develop medications that treat rare diseases?
Department of Health and Human Services
National Organization for Rare Disorders
Food and Drug Administration
Orphan Drug Act
The Correct Answer is D
Choice A reason: The Department of Health and Human Services oversees public health programs and agencies but does not directly provide financial incentives for rare disease drug development.
Choice B reason: The National Organization for Rare Disorders advocates for patients and supports research, but it is not a legislative body and does not enact financial incentive programs.
Choice C reason: The Food and Drug Administration regulates drug approval and safety. While it administers the Orphan Drug Act, it is not the source of the legislation itself.
Choice D reason: The Orphan Drug Act, passed in 1983, provides financial incentives such as tax credits, grant funding, and market exclusivity to encourage pharmaceutical companies to develop treatments for rare diseases affecting fewer than 200,000 people in the U.S.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is D
Explanation
Choice A reason: Administering another 3 mg of flumazenil immediately after a failed response to the initial dose is not recommended due to the risk of precipitating seizures, especially in patients with chronic benzodiazepine use or co-ingestion of pro-convulsant substances. Flumazenil has a narrow therapeutic window and should be titrated cautiously.
Choice B reason: Although smaller incremental doses of flumazenil (e.g., 0.2–1 mg) may be used in some protocols, repeated dosing after a cumulative 3 mg without response is generally discouraged. The risk of adverse effects, particularly seizures, increases with higher cumulative doses.
Choice C reason: Waiting 20 minutes and administering another 3 mg would exceed the recommended maximum cumulative dose of flumazenil, which is typically 3–5 mg. This approach increases the risk of serious complications and is not supported by clinical guidelines.
Choice D reason: If a patient does not respond to a total of 3 mg of flumazenil, further administration is not advised. The lack of response suggests that the cause of altered mental status may not be due to benzodiazepines alone or that the patient has developed tolerance. Supportive care and airway management should be prioritized.
Correct Answer is C
Explanation
Choice A reason: QSEN is an initiative focused on preparing nurses with the knowledge, skills, and attitudes necessary to improve quality and safety in healthcare. It is not a replacement for the Patient’s Bill of Rights.
Choice B reason: The Institute of Medicine’s quality aims (e.g., safe, effective, patient-centered care) are broad goals for healthcare improvement. They do not serve as a direct replacement for the Patient’s Bill of Rights.
Choice C reason: The Patient Care Partnership was introduced by the American Hospital Association to replace the Patient’s Bill of Rights. It outlines what patients should expect during hospitalization, including high-quality care, a clean and safe environment, involvement in care decisions, and protection of privacy.
Choice D reason: HIPAA is a federal law that protects patient health information and privacy. While it complements patient rights, it does not replace the Patient’s Bill of Rights.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.